Clinical efficacy and safety of imatinib in the management of Ph⁺ chronic myeloid or acute lymphoblastic leukemia in Chinese patients

Figures & data

Figure 1 Schematic diagram of the transport and metabolism of imatinib.

Abbreviations: P-gp, P-glycoprotein; OCT1, organic cation transporter 1; CYP, cytochrome P450; BCRP, breast cancer resistance protein.

Table 1 The clinical efficacy of imatinib in Chinese CML patients

Reference number	Author	Publication year	Patients enrolled	Number	Cumulative CCyR	Cumulative MMR	Cumulative CMR
^Citation43	Zhou L	2008	CML	151	76.1%		29.4%
^Citation73	Wang GR	2008	CML	95			39.4%
^Citation74	Zou WY	2008	CML	85	92.9%		26.3%
^Citation75	Zhao Y	2009	CML	116	69.6%		54.9%
^Citation45	Qin Y	2009	CML-CP	56		73.9%
^Citation76	Zhou KS	2010	CML-CP	85	67.1%		36.4%
^Citation50	Jiang Q	2011	CML-AP	132	47.1%	34.5%
^Citation46	Jiang H	2011	CML-CP	171	84.0%	37.0%
^Citation77	Wu SH	2012	CML	155		52.8%
^Citation78	Haiyan He	2012	CML	275	61.9%
^Citation44	Zhou M	2013	CML	214	69.2%	31.3%
^Citation51	Zhou L	2013	CML-CP	37		68.0%

Abbreviations: AP, accelerated phase; CCyR, complete cytogenetic response; CML, chronic myeloid leukemia; CMR, complete molecular response; CP, chronic phase; MMR, major molecular response.

Table 2 The clinical efficacy of imatinib in Chinese Ph⁺ ALL patients

Reference number	Author	Publication year	Patients enrolled	Number	OS
^Citation79	Li Y	2009	Ph^+ ALL (with additional chromosomal abnormalities)	110	1-year (69.5%)
^Citation52	Li CX	2010	Ph^+ ALL	30	3-year (12.4%)
^Citation53	Huang J	2011	Ph^+ ALL	16	3-year (9.3%)
^Citation80	Guo Z	2011	Ph^+ ALL	36	3-year (66.7%)
^Citation55	Chen J	2013	Ph^+ ALL	35	5-year (62.6%)
^Citation54	Zhang FH	2013	Ph^+ ALL	69	3-year (11.4%)

Abbreviations: OS, overall survival; Ph+ ALL, Philadelphia chromosome-positive acute lymphocytic leukemia.

ZhouLWangAHWangL[Efficacy and safety of imatinib in treatment of 151 chronic myeloid leukemia patients]Zhonghua Xue Ye Xue Za Zhi20082911317 Chinese18512309

 PubMedGoogle Scholar

WangGRZhaoYZQianLS[Analysis of long-term treatment outcome and related factors in 95 chronic myeloid leukemia patients treated with imatinib]ZhonghuaXue Ye XueZaZhi20082911822 Chinese

 Google Scholar

ZouWYXuDRSuCLiJLuoSK[Therapeutic effects of imatinib on chronic myeloid leukemia in different phases and the factors affecting the effects]Nan Fang Yi Ke Da XueXueBao200828916601662 Chinese

 Google Scholar

ZhaoYLiuLWangYEfficacy and prognosis of chronic myeloid leukemia treated with imatinib mesylate in a Chinese populationInt J Hematol200989444545119350352

 PubMed Web of Science ®Google Scholar

QinYJiangBJiangQMolecular responses of late chronic phase chronic myeloid leukemia patients after achieving complete cytogenetic responses with imatinib treatment: a 6-year follow-upAnn Hematol2009881374118651143

 PubMed Web of Science ®Google Scholar

ZhouKSWangYYZhaoYZ[Analysis of efficacy and related factors in 85 chronic myeloid leukemia patients treated with imatinib mesylate]Zhongguo Shi Yan Xue Ye XueZaZhi2010181208212 Chinese

 Google Scholar

JiangQXuLPLiuDHImatinib mesylate versus allogeneic hematopoietic stem cell transplantation for patients with chronic myelogenous leukemia in the accelerated phaseBlood2011117113032304021252092

 PubMed Web of Science ®Google Scholar

JiangHChenSSJiangBSeven-year response to imatinib as initial treatment versus re-treatment in Chinese patients with chronic myelogenous leukemia in the chronic phaseAnn Hematol2011901414620668855

 PubMed Web of Science ®Google Scholar

WuSHZhengCPXuJ[A retrospective study of chronic myelocytic leukemia treatment with imatinib and interferon-α]ZhonghuaXue Ye XueZaZhi2012334311315

 Google Scholar

HeHShenYZhuYChenSPrognostic analysis of chronic myeloid leukemia in Chinese population in an imatinib eraFront Med20126220421122660978

 PubMedGoogle Scholar

ZhouMQiuHYHeGS[Multivariate analysis of imatinib resistance-related factors during the treatment of chronic myeloid leukemia]Zhonghua Xue Ye Xue Za Zhi2013345395398 Chinese23688748

 PubMedGoogle Scholar

ZhouLWangJXHuangXJ[Preliminary comparison of efficacy and safety of dasatinib and imatinib in newly diagnosed chronic myeloid leukemia]Zhonghua Xue Ye Xue Za Zhi20133429397 Chinese23611212

 PubMedGoogle Scholar

LiYQiuLZouDZhaoYMiYWangJAdditional chromosomal abnormalities and their prognostic significance in adult Philadelphia-positive acute lymphoblastic leukemia: with or without imatinib in chemotherapyAnn Hematol200988111069107719277658

 PubMed Web of Science ®Google Scholar

LiCXWuDPLiuH[Clinical study of imatinib for treatment of Philadelphia chromosome positive acute lymphoblastic leukemia]Zhonghua Xue Ye Xue Za Zhi2010313181185 Chinese20510109

 PubMedGoogle Scholar

HuangJZouDHFuMW[Imatinib combined with modified hyper-CVAD/MA followed by allogeneic hematopoietic stem cell transplantation in CR1 as the front-line therapy for adult Ph(+) acute lymphoblastic leukemia]Zhonghua Xue Ye Xue Za Zhi20113210673678 Chinese22339825

 PubMedGoogle Scholar

GuoZChenHRLiuXD[Application of imatinib plus Hyper-CVAD chemotherapy regimen in patients with Ph chromosome positive acute lymphocytic leukemia]Zhonghua Yi XueZaZhi2011912013841387

 Google Scholar

ChenJWuDPChenF[Efficacies of hematopoietic stem cell transplantation plus imatinib in the treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia: a comparative study]Zhonghua Yi Xue Za Zhi2013938583587 Chinese23663336

 PubMedGoogle Scholar

ZhangFHLingYWZhaiXThe effect of imatinib therapy on the outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemiaHematology201318315115723394269

 PubMed Web of Science ®Google Scholar